Recherchiere Firmenbekanntmachungen und finanzielle Kennzahlen
EU-Förderung (1.498.400 €): Unterdrückung von Organellendefekten bei menschlichen Krankheiten Hor15.02.2019 EU-Rahmenprogramm für Forschung und Innovation "Horizont"
Auf einen Blick
Text
Unterdrückung von Organellendefekten bei menschlichen Krankheiten
The goal of SOLID is the systematic mapping of genetic suppression for important organelles with impaired fidelity in human disease to uncover new strategies to correct the perturbed state. Functioning of the eukaryotic cell relies on the concerted activity of biological machines, defects in which can cause incurable human disease, including metabolic disorders and neurodegeneration. This is exemplified by malfunctioning mitochondria or lysosomes, for which (alongside environmental triggers) hundreds of causative genes have been identified, but cures are mostly lacking. This is mainly due to the difficulty of drugging loss-of-function mutations, which uniquely alter or entirely remove the gene product. Extensive studies in yeast and initial work in the human system show that cellular modules contain a substantial amount of hidden genetic suppression. Revealing suppressors of disease-defining features of organelle perturbation and targeting those instead of the query mutations, will address the frustrations of drugging an absent factor and etiological diversity. Until now, mutation-based genome-wide suppressor surveys were mostly limited to model organisms and phenotypes yielding growth defects, due to technical hurdles associated with recessive genetics in the human system. However, with the development of a groundbreaking new forward genetics platform that combines genome engineering, ultradeep haploid mutagenesis and direct stratification of fixed mutants, we can now, for the first time, interrogate genetic suppression of human organelle defects independent of cellular fitness. SOLID will also develop new technology to study organelle fidelity in an exhaustive fashion that departs from a gene-centric view point and captures complex phenotypes. Altogether, this will create a new paradigm of 'studying cell biology via genetics' widely applicable to many different biological questions, and reveal urgently needed novel therapeutic possibilities for incurable diseases.
Geförderte Unternehmen:
| Firmenname | Förderungssumme |
| LUDWIG-MAXIMILIANS-UNIVERSITAET MUENCHEN | 1.498.400 € |
Quelle: https://cordis.europa.eu/project/id/804182
Diese Bekanntmachung wurde von Englisch nach Deutsch übersetzt. Die Bekanntmachung bezieht sich auf einen vergangenen Zeitpunkt, und spiegelt nicht notwendigerweise den heutigen Stand wider. Der aktuelle Stand wird auf folgender Seite wiedergegeben: Ludwig-Maximilians-Universität München, München.
Die Visualisierungen zu "LUDWIG-MAXIMILIANS-UNIVERSITAET MUENCHEN - EU-Förderung (1.498.400 €): Unterdrückung von Organellendefekten bei menschlichen Krankheiten"
werden von
North Data
zur Weiterverwendung unter einer
Creative Commons Lizenz
zur Verfügung gestellt.
